Overcoming Limitations in RNA-Based Therapies: A Case Study on Cutaneous Squamous Cell Carcinoma Clinical Data
Time: 11:00 am
day: Day 2 Track 1 AM
Details:
- Immagina Biotechnology has pioneered integrated technologies to study RNA processing and translation in action
- By combining advanced methods for RiboSeq, tRNAseq, and tRNA fragment analysis, we identified a novel biomarker for Minimal Residual Disease in cutaneous squamous cell carcinoma
- This biomarker also presents significant potential as a drug target, opening new avenues for therapeutic development